Navigation Links
Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
Date:12/7/2012

looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2011, and Form 10-Q for the quarter ended September 30, 2012, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., IR
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
2. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
4. Auxilium Announces Appointments to Enhance Leadership Team
5. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
6. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
9. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
10. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... N.C. , May 13 Chimerix, Inc., ... the commencement of a first-in-human study of CMX157, a ... in vitro activity against both tenofovir-sensitive and tenofovir-resistant ... increase efficacy and decrease toxicity as compared to tenofovir, ...
... LA JOLLA, Calif. , May 13 Transdel ... focused on developing topically administered products using its proprietary transdermal ... March 31, 2010 .  The Company also highlighted recent ... , ...
... , DUBLIN and PHILADELPHIA , ... ), the global specialty biopharmaceutical company,announces that its subsidiary Shire LLC has ... Delaware against Actavis Elizabeth LLC and,Actavis Inc. (collectively "Actavis") for the ... and 6,811,794,(the ,794 patent). , , ...
Cached Biology Technology:Chimerix Initiates Phase 1 Study of CMX157 2Chimerix Initiates Phase 1 Study of CMX157 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 2Transdel Pharmaceuticals Reports First Quarter 2010 Results 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 4Transdel Pharmaceuticals Reports First Quarter 2010 Results 5INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 2INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 3
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... 2014 Amidst the astounding complexity of the billions ... the brain, how do nerve cells decide how far ... do they coordinate these events within the developing brain? ... campus of The Scripps Research Institute (TSRI) have shed ... particular protein plays a far more sophisticated role in ...
(Date:7/10/2014)... Ore. Nuclear engineers at Oregon State University have ... device that should help people all over the world ... intensity, and whether or not it poses a health ... to public demand following the nuclear incident in Fukushima, ... what level of radiation they were being exposed to ...
Breaking Biology News(10 mins):Marshall University to partner with international company in drug development venture 2Scripps Florida scientists shed new light on nerve cell growth 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3
... new study published as the cover article for the April ... ) promises to give physicians new ways to reduce deadly ... cord. In the report, scientists from Columbia University, NY, detail ... cells, called astrocytes, use to handle invading viruses and to ...
... Novocell, Inc., a stem cell engineering company, today announced ... covering human definitive endoderm cells, an essential cell for ... developing for use as a cell therapy for diabetes, ... as lungs, intestine, liver, thymus and thyroid. ...
... CORVALLIS, Ore. Studies done with laboratory rats suggest that ... effect in lowering triglycerides, which along with cholesterol levels and ... cardiovascular disease. In the lab animals, supplements of lipoic ... effect were the same in humans which is not ...
Cached Biology News:West Nile virus studies show how star-shaped brain cells cope with infection 2New approach discovered to lowering triglycerides 2New approach discovered to lowering triglycerides 3
... include: Microarray hybridization chamber assembly (1 ... clamp, thumbscrew) Microarray chamber user guide ... intended to be cleaned and reused. The ... Catalog Oligo Microarray kits and all custom ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... modifications of Eagle's medium have ... formulation. The most widely used ... DME is a modification of ... that contains a higher concentration ...
Biology Products: